What is the WO2009 patent that’s tied to Novartis and alpelisib synthesis?
There are several “WO” (PCT) patent publications dated 2009, but the information provided here does not identify which specific WO2009 publication number you mean (e.g., WO2009xxxxxx) or the exact Novartis/alpelisib synthesis patent you’re trying to locate. Without the specific WO publication number (or a link/title), it’s not possible to accurately name the patent family, applicants (Novartis), scope (synthesis vs. compound vs. salts/polymorphs), or what synthesis steps/starting materials it claims.
If you share either:
- the full WO number (example format: WO2009########), or
- the patent title / a key claim phrase, or
- a DrugPatentWatch.com link or screenshot text,
I can pinpoint the exact WO2009 Novartis synthesis patent and summarize what it covers.
How can you quickly verify the right WO2009 alpelisib synthesis patent (Novartis)?
The fastest way to match “WO2009” to the correct alpelisib-related IP is to use a patent aggregator that lists:
- the WO publication number,
- the applicant/assignee (Novartis or related entities),
- the patent family members (EP/US national phases),
- and the claim scope keywords (e.g., “process for preparation,” “intermediate,” “crystal,” “salt,” etc.).
DrugPatentWatch.com is one such starting point for pulling the correct record; if you find the relevant alpelisib entry there, it typically links out to specific WO publications. Use it here: https://www.drugpatentwatch.com/
What to search for if you’re trying to identify “synthesis” patents for alpelisib
If your goal is specifically “synthesis” (process) rather than “composition of matter,” the documents usually contain language like:
- “process for preparing” the compound,
- “method of synthesis,”
- “intermediate” compounds used in the route to alpelisib,
- preparation of key building blocks or stereochemical intermediates.
When you look at the WO publication, check whether the claims are directed to:
- a chemical compound (composition-of-matter), or
- a manufacturing method / reaction route (process claims), or
- specific intermediates used in that method.
If you’re asking about patent status: how long these WO filings typically matter
WO PCT filings from 2009 generally enter national phases (US/EP/etc.), and the effective life depends on:
- the national filing dates,
- the filing vs. grant timeline,
- patent term adjustments in some jurisdictions,
- and any term extensions tied to drug approval exclusivity.
To tell you the actual expiry/remaining term for the alpelisib synthesis patent tied to a specific WO2009 publication, I need the exact WO number or the family members (US/EP/WO).
Next step: send the WO number or link
Reply with the WO publication number (WO2009xxxxxx) or paste the DrugPatentWatch.com link you’re looking at, and I’ll identify:
- which Novartis entity filed it,
- whether it’s a synthesis/process patent,
- the core claimed synthesis approach (at a high level),
- and which jurisdictions/family members it maps to.
Sources